Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4,253 INR | -0.62% | -0.17% | +0.02% |
04-25 | Pfizer Limited Receives Order from Deputy Commissioner, Dehradun - Sector 8: Uttarakhand | CI |
04-02 | Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- With an expected P/E ratio at 39.02 and 33.32 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.02% | 2.35B | B- | ||
+32.95% | 698B | C+ | ||
+26.51% | 568B | B | ||
-4.97% | 358B | C+ | ||
+18.83% | 328B | B- | ||
+3.54% | 283B | C+ | ||
+15.84% | 238B | B+ | ||
+6.68% | 203B | B- | ||
-9.08% | 198B | A+ | ||
+6.70% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PFIZER Stock
- Ratings Pfizer Limited